The assessment of the rationality of the pharmacotherapy of acute respiratory viral infection in the outpatient practice
Acute respiratory viral infections (ARI) and influenza occupy a leading place in the structure of the overall morbidity of the population in most countries.
Aim. To assess the rational prescription of drugs for etiotropic therapy of ARI in the outpatient practice.
Materials and methods. The following materials for research were used: case histories; treatment sheets; the Unified clinical protocol of primary care for adults and children “Acute respiratory infections”; data of the State Formulary of Medicines as of January 2021; the Register of wholesale prices; the weekly “Apteka” (Pharmacy). The methods of retrospective, descriptive, frequency, and VEN-analysis were applied.
Results. According to the research results, using patient histories, it was found that family doctors prescribed 67 drugs by trade names. For etiotropic therapy, 24 drugs were used; it was 37 % of the total number, and 63 % – for symptomatic therapy. Such drugs as Amizon, Aflubin, Amixin, Resistol, Umkalor were for etiotropic therapy (more than 5 prescriptions). None of these drugs is included in the State Formulary of Medicines and the Unified clinical protocol for the treatment of influenza and SARS. Thus, these drugs are without the proven efficiency, safety and cost-effective use.
Conclusions. The study conducted has shown that the drugs prescribed most often do not have an evidence base of efficacy and safety; none of the most frequently prescribed drugs is included in the State Formulary of Medicines and the Unified clinical protocol. A direct relationship between an increase in the number of prescriptions and an increase in price has been proven.
Key words: acute respiratory viral infections; influenza; frequency analysis; VEN-analysis; family doctor.
Okhotnikova, O. M., Sharikadze, O. V., Rudenko, S. M. (2018). Klinichna immunolohiia. Alerholohiia. Infectolohiia, 1 (106), 16-22.
Kramarev, S. O., Yevtushenko, V. V. (2008). Zdorov’ia Ukrainy, 18 (1), 49-50.
Tokarchuk, N. I., Starinets, L. S. (2012). Perynatolohiia i pediatria, 49 (1), 1-5.
Kramarev, S. A., Hrinevich, O. I., Tonkovid, О. B., Vyhivska, О. V. (2014). Suchasna pediatriia. Ukraina, 5 (61), 39-45.
Derzhavnyi formylyar likarskyh zasobiv. (2020). dec.gov.ua. Available at: https://www.dec.gov.ua/materials/chinnij-vipusk-derzhavnogo-formulyara-likarskih-zasobiv/.
Unifikovanyi klinichnyi protocol pervynnoi medychnoi dopomogy doroslym ta dityam. health-medix.com. Available at: http://www.health-medix.com/articles/liki_ukr/2017-11-06/1.pdf.
Kompendium. (2020). compendium.com.ua. Available at: https://compendium.com.ua/.
Spravocnnik lekarstvennych sredstv VIDAL. vidal.ru. Available at: https://www.vidal.ru/.
Dani derzhavnoho reestru optovo-vidpusknyh tsin stanom na 21.01.2021. pharmbase.com.ua. Available at: https://pharmbase.com.ua/ru/optovye-predlozheniya.
Copyright (c) 2021 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).